| Bioactivity | OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain)[1]. OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner[2]. OSU-T315 causes cell death through apoptosis and autophagy[1]. | ||||||||||||
| Invitro | OSU-T315 (Compound 22; 0-5 μM; 24 hours) exhibits high in vitro potency against a panel of prostate and breast cancer cell lines with a IC50 range of 1-2.5 μM[1].OSU-T315 (0-2.5 μM; 24 hours) can reduce YB-1, HER2, and EGFR expression; shows a modest suppressive effect on phosphorylated S6 levels, exhibits dose-dependent suppressive effects on the levels of phospho-ERK1/2 and phospho-p38, while that of phospho-JNK remains unaltered in PC-3 cell[1]. OSU-T315 (0-4 μM; 24 hours) causes autophagy through ILK inhibition[1]. Western Blot Analysis [1] Cell Line: | ||||||||||||
| Name | OSU-T315 | ||||||||||||
| CAS | 2070015-22-2 | ||||||||||||
| Formula | C30H30F3N5O | ||||||||||||
| Molar Mass | 533.59 | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
OSU-T315
CAS: 2070015-22-2 F: C30H30F3N5O W: 533.59
OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signa
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.